You are here

  • Home
  • Archive
  • Volume 21, Issue 3
  • High-sensitivity troponin predicts coronary disease outcomes in type 2 diabetes but yields no benefit in selecting patients for revascularisation

Article Text

Article menu
Download PDFPDF
Therapeutics/Prevention
Randomised controlled trial
High-sensitivity troponin predicts coronary disease outcomes in type 2 diabetes but yields no benefit in selecting patients for revascularisation
  1. Juhani Junttila
  1. Medical Research Center Oulu, University of Oulu and Oulu University Hospital, Oulu, Finland
  1. Correspondence to : Dr Juhani Junttila, Medical Research Center Oulu, University of Oulu and Oulu University Hospital, PO Box 5000, Oulu 90014, Finland; juhani.junttila{at}oulu.fi

http://dx.doi.org/10.1136/ebmed-2016-110405

Statistics from Altmetric.com

    Commentary on: Everett BM, Brooks MM, Vlachos HE, et al., BARI 2D Study Group. Troponin and cardiac events in stable ischemic heart disease and diabetes. N Engl J Med 2015;373:610–20.OpenUrlCrossRefPubMed

    Context

    High-sensitivity troponin (hs-TnT) assays have been developed for early recognition of patients with acute coronary syndrome (ACS). Additionally, hs-TnT has been shown to be a feasible tool for assessing risk among patients with heart failure. Even though efforts have been made to improve prognosis among patients with coronary artery disease (CAD) with high-risk features, most adverse events occur in patients without these features. Therefore, novel risk markers for ‘intermediate risk’ participants are needed. Recent evidence presents hs-TnT as a promising marker for adverse events among patients with stable CAD.1 ,2 The pathophysiological background for these findings and therapeutic …

    View Full Text

    Footnotes

    • Contributors JJ drafted the manuscript of this commentary.

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/